SIRPA and acute myeloid leukemia: Clinical data on anti-CD47 are still incomplete, but the burst of new molecules targeting the CD47/SIRPα axis, including bispecific antibodies and SIRPα/Fc fusion protein antibodies, is likely to significantly change the therapeutic landscape in terms of AML.